Trump Administration caves to pharma on Medicare Part D 'protected classes' reform

Forbes

17 May 2019 - The Trump administration has shelved a proposal that would have stymied egregious price hikes in the Medicare prescription drug program. 

It’s a major win for the drug industry, and a defeat for Trump’s goal of reducing drug prices.

The rule revolved around Medicare’s program for retail prescription drugs bought at pharmacies like CVS or Walgreens, also known as Medicare Part D.

Read Forbes article

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Regulation , Medicare , Pricing